Identifying the barriers to hepatitis B clinical management: the perspectives of people with hepatitis B.
Clinical management, consisting of regular monitoring, and for a minority of people pharmaceutical treatment, reduces hepatitis B disease progression.
Of all people with hepatitis B in Australia, only 13 per cent are clinically managed and of the 5 per cent that do receive pharmaceutical treatment, 20 per cent do not regularly take their medication.
A major gap in the public health response to hepatitis B is to identify the reasons for the reported ‘non-compliance’ of people with hepatitis B to the current model of care or identifying the elements of an effective clinical guideline and future model of care.
This website was developed with the generous support of a donor.
Burnet Institute (Australia) is located on the traditional land of the Boon Wurrung people and we offer our respects to their Elders past and present. We recognise and respect the continuation of cultural, spiritual and educational practices of Aboriginal and Torres Strait Islander peoples of this land.
Oops!
It looks like something may have gone wrong, and some of the resources required to load the page may not have loaded correctly.
